[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dm":84},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,66],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100600129","phase-3-efficacy-and-safety-of-add-on-therapy-with-empagliflozin-in-patients-with-type-2-diabetes-on-a-background-of-alogliptin-and-metformin-100600129",false,"NCT07093476","Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Trial and Open-Label Extension Study to Evaluate the Efficacy and Safety of Add-On Therapy With Empagliflozin for Patients With Inadequately Controlled Type 2 DiabetesMellitus in the Combination Treatment With Metformin and Alogliptin","Inclusion Criteria:\n\n* Adults at the time of signing the Informed Consent Form (ICF)\n* Signed the written ICF voluntarily after being fully informed of the objectives, methods, and effects of the study\n* Diagnosed with T2DM\n\nExclusion Criteria:\n\n* Diagnosed with other types of diabetes than T2DM\n* History of hypersensitivity reaction to the components or drugs of the same class as the IP or the background therapy\n* Uncontrolled severe complications of diabetes","ALL","19 Years",{"count":19,"type":20},171,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","Phase 3 study to assess the Efficacy and Safety of CT-L02-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Alogliptin Combination Therapy.",[26,27,28],"T2DM","Diabete Type 2","DM","RECRUITING","2025-08-07",{"date":32,"type":33},"2025-08-11","ACTUAL",{"date":35,"type":33},"2025-07-18",{"date":37,"type":20},"2027-04",{"name":39,"class":40},"Celltrion","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":41},"100356799","phase-3-clinical-study-evaluating-vildagliptin-versus-vildagliptinmetformin-on-nafld-with-dm-100356799","NCT03925701","Clinical Study Evaluating Vildagliptin Versus Vildagliptin\u002FMetformin on NAFLD With DM","Clinical Study Evaluating the Effectiveness of Vildagliptin Versus Vildagliptin\u002FMetformin on NAFLD With DM","Inclusion Criteria:\n\n* NAFLD and type 2 DM\n\nExclusion Criteria:\n\n* Viral hepatitis.\n* Child score more than 6.\n* renal impairment.","18 Years",{"count":51,"type":20},120,[23],"Clinical study evaluating vildagliptin versus vildagliptin\u002Fmetformin on NAFLD with DM.",[55],"dm","2019-04-26",{"date":58,"type":33},"2019-04-29",{"date":60,"type":33},"2019-04-01",{"date":62,"type":20},"2028-12",{"name":64,"class":65},"Sherief Abd-Elsalam","OTHER",{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":21,"phases":75,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":82,"leadSponsor":83,"locationsCount":41},"100356800","phase-3-impact-of-p53-and-sirt1-in-type-2-diabetes-100356800","NCT03925714","Impact of P53 and SIRT1 in Type 2 Diabetes","Investigating the Impact of p53 and SIRT1 in the Development of Type 2 DM Through the Treatment of Prediabetic Individuals by Either Nigetella Salivata or Metformin","Inclusion Criteria:\n\n* Prediabetic subjects.\n\nExclusion Criteria:\n\n* Confirmed diabetes.\n* Hepatic or renal impairment.",{"count":74,"type":20},90,[23],"Investigating the impact of p53 and SIRT1 in the development of type 2 DM",[28],"2019-04-22",{"date":80,"type":33},"2019-04-24",{"date":60,"type":33},{"date":62,"type":20},{"name":64,"class":65},""]